Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/tirzepatide/missouri/kansas-city
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Kansas City, MO

Verified Tirzepatide providers in Kansas City, MO. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
38
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Missouri
38 of 38 shown

Find a Tirzepatide provider in Missouri.

Every entry is checked against the NPI registry and the Missouri medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Missouri city · /tirzepatide/missouri/{city}
Springfield
37 →
St Louis
27 →
§ 03Getting Tirzepatide in Kansas City
38 providers · Kansas City, MO

How to get Tirzepatide in Kansas City.

38 GLP-1 prescribers and 7 local resource types are on record for Kansas City, plus 2 nearby towns in the directory.

Prescribers in Kansas City
38 prescribers
38 GLP-1 prescribers in Kansas City, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (15), Family Medicine (13) and Internal Medicine (5). Any Missouri-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Springfield (37 providers) and St Louis (27 providers).
Around the prescription in Kansas City
7 listed nearby
6 dietitians, 4 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Kansas City.
Medicaid (weight loss)
Covered
As of April 2026, Missouri Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Missouri’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Missouri

Diagnosed diabetes reaches 10.7% of adults in Missouri.

of Missouri adults have obesity
34.6%
diagnosed diabetes
10.7%

Age-adjusted estimates for Missouri, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossOzempic side effects in men
§ 05Support around Tirzepatide in Kansas City
6 gyms

The prescription is one part. Here is the rest, in Kansas City.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Kansas City, MO, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Planet Fitness
GYM
4.4 on Google · 1522 reviews
2415 North NE Vivion Rd
Website
Planet Fitness
GYM
4.4 on Google · 1236 reviews
6765 Johnson Dr
Website
Platte County Community Center South-YMCA
GYM
4.6 on Google · 788 reviews
8875 Clark Ave
Website
Genesis Health Clubs - Vivion Road
GYM
4.5 on Google · 702 reviews
1141 NE Vivion Rd
Website
Metro KC Fitness - Strawberry Hill
GYM
4.8 on Google · 589 reviews
607 Tauromee Ave
Website
The Foundation Liberty 24hr Gym
GYM
4.9 on Google · 420 reviews
9521 NE 79th St
Website

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Genesis Health Clubs - Power & Light
FITNESS
4.5 on Google · 768 reviews
1261 Main St
Website
Metro KC Fitness - Argentine
FITNESS
4.8 on Google · 452 reviews
2810 Metropolitan Ave
Website
Metro KC Fitness - Downtown
FITNESS
4.8 on Google · 404 reviews
320 E 12th St
Website
Metro KC Fitness - Briarcliff
FITNESS
4.9 on Google · 356 reviews
4157 N Mulberry Dr
Website
Cleaver Family YMCA
FITNESS
4.6 on Google · 291 reviews
7000 Troost Ave
Website
UMKC Campus Recreation
REC CENTER
4.5 on Google · 288 reviews
5030 Holmes St
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Missouri

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Weight loss doctors in Missouri
Board-certified prescribers verified against the NPI registry.
Weight loss clinics in Missouri
Clinics running GLP-1 programs, telehealth & in-person.
Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Tirzepatide in Alabama→Tirzepatide in Alaska→Tirzepatide in Arizona→Tirzepatide in Arkansas→Tirzepatide in California→Tirzepatide in Colorado→Tirzepatide in Connecticut→Tirzepatide in Delaware→Tirzepatide in Florida→Tirzepatide in Georgia→Tirzepatide in Hawaii→Tirzepatide in Idaho→Tirzepatide in Illinois→Tirzepatide in Indiana→Tirzepatide in Iowa→Tirzepatide in Kansas→Tirzepatide in Kentucky→Tirzepatide in Louisiana→Tirzepatide in Maine→Tirzepatide in Maryland→Tirzepatide in Massachusetts→Tirzepatide in Michigan→Tirzepatide in Minnesota→Tirzepatide in Mississippi→Tirzepatide in Missouri→Tirzepatide in Montana→Tirzepatide in Nebraska→Tirzepatide in Nevada→Tirzepatide in New Hampshire→Tirzepatide in New Jersey→Tirzepatide in New Mexico→Tirzepatide in New York→Tirzepatide in North Carolina→Tirzepatide in North Dakota→Tirzepatide in Ohio→Tirzepatide in Oklahoma→Tirzepatide in Oregon→Tirzepatide in Pennsylvania→Tirzepatide in Rhode Island→Tirzepatide in South Carolina→Tirzepatide in South Dakota→Tirzepatide in Tennessee→Tirzepatide in Texas→Tirzepatide in Utah→Tirzepatide in Vermont→Tirzepatide in Virginia→Tirzepatide in Washington→Tirzepatide in West Virginia→Tirzepatide in Wisconsin→Tirzepatide in Wyoming→
Related GLP-1 research
the tirzepatide dosing schedule
Starting dose, step-ups, and the 2.5-to-15 mg ladder.
do oral GLP-1 pills work
Pills and drops vs injections: what the evidence supports.
§ 09Frequently asked: Tirzepatide in Missouri

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]